Both Companies

Also showing items for Both Research

 
Stock Quotes for Both Companies top ^
  • Industry: Conglomerates
  • Sector: Industrials
  • Stock Type: Cyclical
Sign-up for both investment picks
  • Industry: Conglomerates
  • Sector: Industrials
  • Stock Type: Cyclical
Sign-up for both investment picks

 
News Articles for Both Companies top ^
2015/2/2
By Josie Cox And Neil MacLucas The value of the Swiss franc dropped to two-week lows against both the euro and the U.S. dollar on Monday, with strategists pointing to a local media report that the Swiss National Bank is unofficially operating a currency corridor and intervening to stem the franc's rally.
Sign-up for Swiss Franc Drops to Two-Week Lows Against Both Dollar and Euro -- Update investment picks
2015/2/2
By Josie Cox And Neil MacLucas The value of the Swiss franc dropped to two-week lows against both the euro and the U.S. dollar on Monday, with strategists pointing to a local media report that the Swiss National Bank is unofficially operating a currency corridor and intervening to stem the franc's rally.
Sign-up for Swiss Franc Drops to Two-Week Lows Against Both Dollar and Euro investment picks
2014/12/22
First Trust Intermediate Duration Preferred & Income Fund (the “Fund”) (NYSE: FPF) has declared the Fund’s regularly scheduled monthly common share distribution and special distribution, both in the amount of $0.1625 per share payable on January 15, 2015, to shareholders of record as of December 31, 2014.
Sign-up for First Trust Intermediate Duration Preferred & Income Fund Declares its Monthly Common Share Distribution and Special Distribution, both in the amount of $0.1625 Per Share investment picks
2015/2/2
By Josie Cox And Neil MacLucas The Swiss franc tumbled to a two-week low against both the euro and the U.S. dollar Monday, with strategists pointing to a local media report that the Swiss National Bank is unofficially operating a currency corridor and intervening to stem the franc's rally.
Sign-up for Swiss Franc Drops to Two-Week Lows Against Both Dollar and Euro -- 2nd Update investment picks
2015/1/14
AstraZeneca (NYSE:AZN) today announced that the PEGASUS-TIMI 54 study, a large scale outcomes trial involving over 21,000 patients, successfully met its primary efficacy endpoint.
Sign-up for PEGASUS-TIMI 54 Study of BRILINTA® Meets Primary Endpoint in Both 60mg and 90mg Doses investment picks
2015/1/16
Celgene International Sàrl (NASDAQ: CELG), a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission (EC) has granted marketing authorisation for OTEZLA ® (apremilast), the company’s oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications: 1 “The approval of OTEZLA ® is an important new option for the treatment of patients who are not experiencing adequate relief for their conditions.
Sign-up for Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis investment picks
2015/1/28
http://www.marketwire.com/library/MwGo/2015/1/27/11G031539/rg_green-998786622155.jpg TORONTO, ON--(Marketwired - January 28, 2015) - Ross' Gold™ a subsidiary of Green and Hill Industries Inc. (OTC: GHIL) (the "Company") today announced that it has signed a licensing agreement with Canna Products USA (CP USA)to manufacture, distribute and sell a line of Ross' Gold™ Hemp and CBD (Cannabidiol) products to their customers through online channels and third party retail outlets in the USA.
Sign-up for Ross' Gold Signs Licensing Agreement With Canna Products USA Inc. for Line of Hemp and CBD Products to Be Sold Both Online and Through Retail Outlets investment picks
2015/1/27
3M (NYSE:MMM) today reported fourth-quarter earnings of $1.81 per share, an increase of 11.7 percent versus the fourth quarter of 2013.
Sign-up for 3M Announces Fourth-Quarter Results; Company Posts Record Sales and Earnings per Share for Both Fourth Quarter and Full Year investment picks
2015/1/22
J.B. Hunt Transport Services, Inc., (NASDAQ:JBHT) announced fourth quarter 2014 net earnings of $110 million, or diluted earnings per share of 93 cents vs.
Sign-up for J.B. Hunt Transport Services, Inc. Reports Revenues, Net Earnings and Earnings Per Share for Both the Fourth Quarter and Year Ended December 31, 2014 investment picks
2015/2/24
- Exceeded upper end of guidance range with full year comparable RevPAR Growth of 8.0% and Pro Forma Adjusted EBITDA of $375.5 million - Generated full year Pro Forma Earnings per Share of $0.45 - Opened 45 franchise locations in 2014 and increased pipeline 11% - Repaid $205 million of long-term debt in 2014, including $195 million of voluntary prepayments IRVING, Texas , Feb.
Sign-up for La Quinta Holdings Inc. Reports Strong Results For Both Fourth Quarter And Full Year 2014 investment picks
2015/2/24
> CGI's genomic signature, developed in a research collaboration with Memorial Sloan-Kettering, predicts metastasis for clear-cell renal cell carcinoma (ccRCC) > Clear cell renal cell carcinoma is the most common form of kidney cancer with nearly 43,000 new cases in the US each year and 200,000 globally per year RUTHERFORD, N.J., Feb.
Sign-up for Cancer Genetics Inc to Present New Data on Identification of Genomic Changes That Predict Both Metastasis and Site of Metastasis in Kidney Cancer at the 2015 ASCO Genitourinary Cancers Symposium investment picks
2015/2/20
EDGEWELL PERSONAL CARE AS NEW NAME FOR PERSONAL CARE COMPANY NEW ENERGIZER WILL MAINTAIN ENERGIZER HOLDINGS, INC.
Sign-up for Energizer Holdings Announces Names For Both New Companies Upon Separation On July 1, 2015 investment picks
2015/2/19
Live demos of the system will be presented at Camtek's booth in IPC APEX next week MIGDAL HAEMEK, Israel , February 19, 2015 /PRNewswire/ -- Camtek Ltd.
Sign-up for Camtek Unveils Gryphon SL - its 3D Functional Inkjet Technology System Enabling Both Solder Mask and Legend Deposition - at IPC APEX EXPO investment picks
2015/2/18
In patients with moderate or worse vision loss at baseline, those treated with EYLEA gained, on average, an additional full line or more on an eye chart when compared to those treated with alternative anti-VEGF therapies Results Published in New England Journal of Medicine TARRYTOWN, N.Y. , Feb.
Sign-up for NIH-Sponsored Comparative Effectiveness Trial in Diabetic Macular Edema Shows EYLEA® (aflibercept) Injection Demonstrated Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab investment picks
2015/2/9
SPARTANBURG, S.C., Feb.
Sign-up for Synalloy Reports Substantial Gains in Profits From Continuing Operations for Both the Fourth Quarter and Year of 2014 investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Both Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Boston Private Financial  |  Next: Both Research